Sichuan Baili Pharmaceutical Co., Ltd.
Last updated Jul 29, 2026
Evidence Sources
2
Competitive Findings
0
Portfolio Developments
0
Regulatory Precedents
8
Clinical Programs
0
Confidence Coverage
66%
Audit
- Competitor findings: 0
- Portfolio developments: 0
- Self-competition findings removed: 0
- Unknown ownership findings removed: 0
Executive Summary
Material intelligence activity detected across:
- Oncology
- NSCLC
- Non-small Cell Lung Cancer
Highest priority development: Verified Clinical Benefit | Cancer Accelerated Approvals
Regulatory precedent
Why this matters: sets a approval precedent in the same sub-indication (lung cancer) as Sichuan Baili Pharmaceutical Co., Ltd..
Competitive pressure: Low
Portfolio impact: High
Evidence coverage: 66%
Active Signals
2
Investigate Priority
0
Opportunity Score
41
Buyer Quality
7 · Emerging
Recent Signals
Latest intelligence events linked to this organization.
- MonitorJul 29, 2026Score 21Phase II/III Trial of BL-B01D1 with Osimertinib in EGFR-mutant NSCLC Initiated
Oncology · NSCLC
- MonitorJul 25, 2026Score 20Phase II Study of BL-B01D1 with PD-1 Antibody in Advanced Lung Cancer and Other Tumors
Oncology · Non-small Cell Lung Cancer
Related Assets
Portfolio asset pages with evidence-based assessments.
No linked asset pages are available yet.
Portfolio Development
Owned-asset pipeline events — Phase III readouts, approvals, label expansions, and deals. Not classified as competitive threats.
No portfolio development items are linked to this company yet.
Competitive Intelligence Findings
Competitiva findings with evidence, reasoning, and confidence calibration.
No Competitiva findings are linked to this company yet.
Regulatory Developments
Regunera precedents with source attribution and confidence disclosure.
- Verified Clinical Benefit | Cancer Accelerated ApprovalsLow Confidence · 54%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - Cancer Clinical Trial Eligibility Criteria: Performance StatusModerate Confidence · 72%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - Cancer Clinical Trial Eligibility Criteria: Laboratory ValuesModerate Confidence · 72%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - Cancer Clinical Trial Eligibility Criteria: Washout Periods and Concomitant MedicationsModerate Confidence · 72%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera
Clinical Developments
Pipeline activity with auditable evidence and uncertainty disclosure.
No clinical developments are linked yet.
Capital Markets
SEC filings, IPO activity, and capital markets events from the Business Intelligence Layer.
No capital markets intelligence is available yet.
Financing History
Venture funding, follow-on offerings, PIPE financings, and debt financing.
No financing history is available yet.
Licensing & Partnerships
Licensing agreements, strategic partnerships, and distribution deals.
No licensing or partnership activity is available yet.
M&A Activity
Acquisitions, mergers, and divestitures.
No M&A activity is available yet.
Investor Activity
Earnings releases, investor presentations, and conference appearances.
No investor activity is available yet.
Executive Changes
CEO appointments, board changes, and leadership restructuring.
No executive changes are available yet.
Business Timeline
Chronological business intelligence events across financing, licensing, M&A, and commercial strategy.
No business timeline events are available yet.
Strategic Signals
Higher-order strategic intelligence fused from regulatory, scientific, business, and competitive events. Signals answer what it means — not just what happened.
Strategic signals will appear once sufficient event convergence is detected.
Investigate-Priority Items
Signals flagged for investigation or escalation — highest urgency for portfolio review.
No investigate-priority signals are active for this company.
Humanexa Agent Questions
Suggested prompts to explore this organization's intelligence profile. Open a linked signal to ask the agent.
- What are the most material competitive threats to Sichuan Baili Pharmaceutical Co., Ltd. right now?
- Which regulatory precedents should Sichuan Baili Pharmaceutical Co., Ltd. monitor in Oncology and NSCLC?
- Which pipeline programs should Sichuan Baili Pharmaceutical Co., Ltd. prioritize for competitive review?
- What signals require immediate investigation for Sichuan Baili Pharmaceutical Co., Ltd.?
- Summarize the strategic implications of recent developments for Sichuan Baili Pharmaceutical Co., Ltd..
- Where is the greatest uncertainty in Sichuan Baili Pharmaceutical Co., Ltd.'s competitive positioning?